Journal of Neuro-Oncology

, Volume 91, Issue 3, pp 271–277 | Cite as

Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C

  • Marc C. Chamberlain
  • Sandra K. Johnston
  • Alixis Van Horn
  • Michael J. Glantz
Clinical study - patient Study


Background The most frequent central nervous system complication of systemic non-Hodgkin’s lymphoma (NHL) is lymphomatous meningitis (LM). Objective A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. Design Clinical series of 14 patients with CSF positive lymphomatous meningitis. Setting Tertiary-care university medical center. Results Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1–6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. Conclusions The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.


Lymphomatous meningitis Intra-CSF liposomal ara-C and rituximab 


  1. 1.
    Recht L, Straus DJ, Cirrincione C et al (1988) Central nervous system metastases from non-Hodgkin’s lymphoma: treatment and prophylaxis. Am J Med 84:425–435PubMedCrossRefGoogle Scholar
  2. 2.
    Haioun C, Besson C, Lepage E et al (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol 11:685–690PubMedCrossRefGoogle Scholar
  3. 3.
    Hollender A, Kvaloy S, Lote K et al (2000) Prognostic factors in 140 adult patients with non-Hodgkin’s lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 36:1762–1768PubMedCrossRefGoogle Scholar
  4. 4.
    Jahnke K, Thiel E, Martus P et al (2006) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85:45–50PubMedCrossRefGoogle Scholar
  5. 5.
    Bollen EL, Brouwer RE, Hamers S et al (1997) Central nervous system relapses in non-Hodgkin lymphoma. A single-centre study of 532 patients. Arch Neurol 54:854–859PubMedGoogle Scholar
  6. 6.
    Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1,693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol 18:149–157PubMedCrossRefGoogle Scholar
  7. 7.
    Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11:561–569PubMedGoogle Scholar
  8. 8.
    Hitchens R, Bell D, Woods R et al (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655–1662Google Scholar
  9. 9.
    Glantz M, Jaeckle KA, Chamberlain MC et al (1999) A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116PubMedGoogle Scholar
  10. 10.
    Glantz M, Jaeckle K, Chamberlain MC et al (1999) A randomized trial comparing intrathecal sustained-release ara-C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402PubMedGoogle Scholar
  11. 11.
    Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40:2726–2733PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan EL, Meier P (1958) Nonparametric estimation form incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  13. 13.
    Guruangan S, Pedros WP, Poussaint TY et al (2008) Phase 1 trial of intrathecal spartaject busulfan in children with neoplastic meningitis; a pediatric brain tumor consortium study (PBTC-004). Clin Cancer Res 12:1540–1546CrossRefGoogle Scholar
  14. 14.
    Chamberlain MC, Wei-Tao DD, Groshen S (2006) A Phase II trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer 31(9):2021–2027CrossRefGoogle Scholar
  15. 15.
    Rubenstein JL, Coombs D, Rosenberg J et al (2003) Rituximab in CNS lymphoma; targeting the leptomeningeal compartment. Blood 101:466–468PubMedCrossRefGoogle Scholar
  16. 16.
    Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase 1 study of intraventricular administration of rituximab in patients with recurrent CNS and intra-ocular lymphoma. J Clin Oncol 25(11):1350–1356PubMedCrossRefGoogle Scholar
  17. 17.
    Glantz MJ, Cole BF, Recht L (1998) High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: is intrathecal hemotherapy necessary? J Clin Oncol 16(4):1561–1567PubMedGoogle Scholar
  18. 18.
    Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (1983) Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1(9):546–551PubMedGoogle Scholar
  19. 19.
    Maria BL, Boss TF, Guzman GA, Gouveia WA, White CA, Strauss MJ (1996) Cost of treating leptomeningeal metastases with intrathecal DepofoamTM encapsulated cytarabine. Presented at 1996 American society of clinical oncologists annual meeting, 18–21 May 1996, Philadelphia, Pennsylvania. Proc Am Soc Clin Oncol 15:160 (abstract 305)Google Scholar
  20. 20.
    Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol 18:149–157PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Marc C. Chamberlain
    • 1
  • Sandra K. Johnston
    • 2
  • Alixis Van Horn
    • 3
  • Michael J. Glantz
    • 4
  1. 1.Department of Neurology, Division of Neuro-OncologyUniversity of Washington, Fred Hutchinson Cancer Research Center Seattle Cancer Care AllianceSeattleUSA
  2. 2.Department of Neurology, Division of Neuro-OncologyUniversity of Washington and Seattle Cancer Care AllianceSeattleUSA
  3. 3.Department of NeurologyTufts Medical CenterBostonUSA
  4. 4.Departments of Oncology and NeurosurgeryUniversity of Utah/Huntsman Cancer InstituteSalt Lake CityUSA

Personalised recommendations